Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.

Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson K, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW.

Clin Cancer Res. 2018 Oct 1;24(19):4771-4784. doi: 10.1158/1078-0432.CCR-17-2773. Epub 2018 Mar 21.

2.

Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.

Mender I, Gryaznov S, Dikmen ZG, Wright WE, Shay JW.

Cancer Discov. 2015 Jan;5(1):82-95. doi: 10.1158/2159-8290.CD-14-0609. Epub 2014 Dec 16.

3.

Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors.

Sengupta S, Sobo M, Lee K, Senthil Kumar S, White AR, Mender I, Fuller C, Chow LML, Fouladi M, Shay JW, Drissi R.

Mol Cancer Ther. 2018 Jul;17(7):1504-1514. doi: 10.1158/1535-7163.MCT-17-0792. Epub 2018 Apr 13.

4.
5.

Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.

Mender I, LaRanger R, Luitel K, Peyton M, Girard L, Lai TP, Batten K, Cornelius C, Dalvi MP, Ramirez M, Du W, Wu LF, Altschuler SJ, Brekken R, Martinez ED, Minna JD, Wright WE, Shay JW.

Neoplasia. 2018 Aug;20(8):826-837. doi: 10.1016/j.neo.2018.06.002. Epub 2018 Jul 6.

6.

Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.

Reyes-Uribe P, Adrianzen-Ruesta MP, Deng Z, Echevarria-Vargas I, Mender I, Saheb S, Liu Q, Altieri DC, Murphy ME, Shay JW, Lieberman PM, Villanueva J.

Oncogene. 2018 Jul;37(30):4058-4072. doi: 10.1038/s41388-018-0247-7. Epub 2018 Apr 26.

7.

Playing the Melanoma Endgame.

Teh JLF, Aplin AE.

Clin Cancer Res. 2018 Oct 1;24(19):4629-4630. doi: 10.1158/1078-0432.CCR-18-0989. Epub 2018 May 16.

9.

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M.

Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16.

10.

Highly Aggressive Metastatic Melanoma Cells Unable to Maintain Telomere Length.

Viceconte N, Dheur MS, Majerova E, Pierreux CE, Baurain JF, van Baren N, Decottignies A.

Cell Rep. 2017 Jun 20;19(12):2529-2543. doi: 10.1016/j.celrep.2017.05.046.

11.

Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.

Rachakonda S, Kong H, Srinivas N, Garcia-Casado Z, Requena C, Fallah M, Heidenreich B, Planelles D, Traves V, Schadendorf D, Nagore E, Kumar R.

Genes Chromosomes Cancer. 2018 Nov;57(11):564-572. doi: 10.1002/gcc.22669. Epub 2018 Sep 11.

PMID:
30203894
12.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.

Ben-Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S.

Clin Cancer Res. 2017 May 1;23(9):2289-2300. doi: 10.1158/1078-0432.CCR-16-1930. Epub 2016 Nov 17.

13.

TERT promoter mutations in telomere biology.

Heidenreich B, Kumar R.

Mutat Res. 2017 Jan - Mar;771:15-31. doi: 10.1016/j.mrrev.2016.11.002. Epub 2016 Nov 23. Review.

PMID:
28342451
14.

Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis.

Biroccio A, Amodei S, Antonelli A, Benassi B, Zupi G.

J Biol Chem. 2003 Sep 12;278(37):35693-701. Epub 2003 Jun 24.

16.

Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.

Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, Harley CB, Rudolph KL.

Hepatology. 2005 Nov;42(5):1127-36.

PMID:
16114043
17.

Quantitative proteomic profiling of tumor cell response to telomere dysfunction using isotope-coded protein labeling (ICPL) reveals interaction network of candidate senescence markers.

Biniossek ML, Lechel A, Rudolph KL, Martens UM, Zimmermann S.

J Proteomics. 2013 Oct 8;91:515-35. doi: 10.1016/j.jprot.2013.08.007. Epub 2013 Aug 19.

PMID:
23969227
18.

Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: correlation with sensitivity to DNA damaging agents.

Villa R, Folini M, Perego P, Supino R, Setti E, Daidone MG, Zunino F, Zaffaroni N.

Int J Oncol. 2000 May;16(5):995-1002.

PMID:
10762636
19.

Turning telomerase into a Jekyll and Hyde case?

Wellinger RJ.

Cancer Discov. 2015 Jan;5(1):19-21. doi: 10.1158/2159-8290.CD-14-1346.

20.

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases.

Bai X, Kong Y, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J, Si L.

Clin Cancer Res. 2017 Oct 15;23(20):6120-6127. doi: 10.1158/1078-0432.CCR-17-0980. Epub 2017 Jul 18.

Supplemental Content

Support Center